Last reviewed · How we verify
Treatment G
Treatment G is a Small molecule drug developed by AstraZeneca. It is currently FDA-approved.
Treatment G is not a recognized branded pharmaceutical product in standard drug databases.
Treatment G, also known as GSK1278863, is a small molecule being studied in clinical trials for various conditions, including anaemia, Rett Syndrome, and Ulcerative Colitis. It is being investigated as a potential treatment in combination with iron and trofinetide in these trials.
At a glance
| Generic name | Treatment G |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without additional context or a specific drug name, it is not possible to provide an accurate mechanistic description. 'Treatment G' appears to be a placeholder or internal designation rather than an established marketed drug.
Approved indications
Common side effects
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment G CI brief — competitive landscape report
- Treatment G updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Treatment G
What is Treatment G?
How does Treatment G work?
Who makes Treatment G?
What development phase is Treatment G in?
Related
- Manufacturer: AstraZeneca — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing